WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced that The New England Journal of Medicine (NEJM) published results from the pivotal Phase III RESPONSE clinical trial demonstrating that, compared to standard therapy, Jakafi® (ruxolitinib) significantly improved hematocrit control and reduced spleen volume in patients with polycythemia vera (PV) who had an inadequate response to or had unacceptable side effects from hydroxyurea1. PV is a myeloproliferative neop
| < Prev | Next > |
|---|
